Heinz Kobelt, secretary general of the European parallel drug traders' association (EAEPC), has attacked the recent report on fake drugs from the European Alliance for Access to Safe Medicines (Marketletter November 26). Dr Kobelt said: "this kind of report makes no contribution to the patient safety debate. Published by an un-transparent, industry-funded 'patient safety alliance,' the report is about discrediting the legitimate and safe practice of European Union-internal distribution of medicines which introduces price competition for manufacturers."
He added that, "unfortunately, this kind of black propaganda risks distracting policymakers and the public from the real threats to patient health, such as illegal Internet sales of medicines. We would suggest that the report's author, Jonathan Harper, at least speak to or visit a parallel distributor before writing his next report on parallel trade."
EAASM's structure "is entirely transparent"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze